Ann: Investor Presentation, 8 January 2015, page-37

Sure coppertop,

From the 14th Nov ann.

The probability of observing this combined degree of clinical benefit
both in the group level and subject -level analyses and no clinically
significant worsening in any endpoint purely by chance (the “false -
positive” rate) as determined as 2.3% (p=0.023) by permutation testing.
In the permutation testing,randomly simulated allocations of patients to NNZ- 2566 and placebo were repeated 1000 times and positive outcomes
in the data were counted. The statistical approach used in the analysis of the trial results, including permutation testing, has been published in a peer-reviewed journal and used in previous trials in other therapeutic areas, including for the development of a product recently granted Breakthrough Therapy designation by the FDA